[go: up one dir, main page]

MX2025004265A - Conjugado anticuerpo-farmaco que contiene un compuesto agonista dual del receptor tipo toll 7/8 - Google Patents

Conjugado anticuerpo-farmaco que contiene un compuesto agonista dual del receptor tipo toll 7/8

Info

Publication number
MX2025004265A
MX2025004265A MX2025004265A MX2025004265A MX2025004265A MX 2025004265 A MX2025004265 A MX 2025004265A MX 2025004265 A MX2025004265 A MX 2025004265A MX 2025004265 A MX2025004265 A MX 2025004265A MX 2025004265 A MX2025004265 A MX 2025004265A
Authority
MX
Mexico
Prior art keywords
antibody
drug complex
salt
present
cancer
Prior art date
Application number
MX2025004265A
Other languages
English (en)
Inventor
Michinori Akaiwa
Yohei Seki
Yinghua Wang
Javier Ramos Miguelez
Kei Ohnuki
Takashi Kamikubo
Toru Asano
Akio Kamikawa
Takashi Chaen
Rika Hoshi
Shinji Soga
Chulwon Kwon
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2025004265A publication Critical patent/MX2025004265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El objeto de la presente invención proporciona una composición farmacéutica para prevenir o tratar diversos tipos de cáncer mediante el desarrollo de un conjugado anticuerpo-fármaco o una sal del mismo que contiene un compuesto agonista dual de TLR7/8. Los presentes inventores encontraron un compuesto o una sal del mismo que tiene una acción agonista dual de TLR7/8, estudiaron un conjugado anticuerpo-fármaco que se puede usar como ingrediente activo de una composición farmacéutica para prevenir o tratar varios tipos de cáncer y encontraron/aclararon que el conjugado anticuerpo-fármaco o una sal del mismo de acuerdo con la presente invención tiene un efecto sobre la producción de TNF-a e INF-? y un efecto antitumoral in vivo y se puede usar para la prevención o el tratamiento del cáncer. También encontraron un anticuerpo anti CLDN6 para usarse en un conjugado anticuerpo-fármaco o una sal del mismo de acuerdo con la presente invención. El conjugado anticuerpo-fármaco que contiene un compuesto agonista dual de TLR7/8 o una sal del mismo de acuerdo con la presente invención y el compuesto de fórmula (II) o una sal del mismo de acuerdo con la presente invención tiene un efecto sobre la producción de TNF-a e INF-? y un efecto antitumoral in vivo y se espera que se utilice en un agente profiláctico o terapéutico para el cáncer.
MX2025004265A 2022-10-31 2025-04-10 Conjugado anticuerpo-farmaco que contiene un compuesto agonista dual del receptor tipo toll 7/8 MX2025004265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022174538 2022-10-31
PCT/JP2023/039102 WO2024095964A1 (ja) 2022-10-31 2023-10-30 Ｔｏｌｌ様受容体７／８デュアルアゴニスト化合物を含む抗体薬物複合体

Publications (1)

Publication Number Publication Date
MX2025004265A true MX2025004265A (es) 2025-05-02

Family

ID=90930522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025004265A MX2025004265A (es) 2022-10-31 2025-04-10 Conjugado anticuerpo-farmaco que contiene un compuesto agonista dual del receptor tipo toll 7/8

Country Status (10)

Country Link
US (2) US12390536B2 (es)
EP (1) EP4566633A1 (es)
JP (1) JPWO2024095964A1 (es)
KR (1) KR20250097820A (es)
CN (1) CN119947760A (es)
AR (1) AR130904A1 (es)
AU (1) AU2023373601A1 (es)
MX (1) MX2025004265A (es)
TW (1) TW202434302A (es)
WO (1) WO2024095964A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9274119B2 (en) 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
DK2499161T3 (da) 2009-11-11 2017-11-27 Ganymed Pharmaceuticals Gmbh Antistoffer, der er specifikke for claudin 6 (cldn6)
CN107011440B (zh) 2011-05-13 2021-03-05 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
PT2796550T (pt) 2011-12-22 2018-04-18 Astellas Pharma Inc Novo anticorpo ctgf anti-humano
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
SG11201608299TA (en) 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
MA44334A (fr) * 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US10487084B2 (en) * 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
CN113164618A (zh) 2018-09-12 2021-07-23 希沃尔拜克治疗公司 用免疫刺激性缀合物治疗疾病的方法和组合物
US12534465B2 (en) 2019-06-10 2026-01-27 Sutro Biopharma, Inc. 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
WO2020252015A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
TW202126658A (zh) * 2019-09-29 2021-07-16 大陸商江蘇恆瑞醫藥股份有限公司 吡咯并雜芳基衍生物或其偶聯物、其製備方法及其應用
CA3151322A1 (en) * 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
TW202227478A (zh) 2020-09-15 2022-07-16 德商拜恩迪克公司 對細胞靶向遞送的藥劑及方法
JP6976016B1 (ja) 2021-05-11 2021-12-01 ガルファ株式会社 化石資源増量装置

Also Published As

Publication number Publication date
KR20250097820A (ko) 2025-06-30
EP4566633A1 (en) 2025-06-11
US20250312471A1 (en) 2025-10-09
TW202434302A (zh) 2024-09-01
US12390536B2 (en) 2025-08-19
CN119947760A (zh) 2025-05-06
WO2024095964A1 (ja) 2024-05-10
AU2023373601A1 (en) 2025-04-03
JPWO2024095964A1 (es) 2024-05-10
AR130904A1 (es) 2025-01-29
US20250025567A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
MX2024011056A (es) Compuesto heterociclico para inducir la degradacion de la proteina kras mutante g12d.
ZA202307791B (en) Quinazoline compound for inducing degradation of g12d mutant kras protein
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2024006681A (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2025000772A (es) Compuesto heterociclico que actua sobre la proteina kras mutante g12d
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
MX2023006318A (es) Compuesto de heteroarilcarboxamida.
MA56748B1 (fr) Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
MX2023007140A (es) Compuestos farmaceuticos.
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2019012827A (es) Derivados de tetrahidronaftilo urea novedosos.
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2024002409A (es) Terapias contra el cancer.
MX2025004265A (es) Conjugado anticuerpo-farmaco que contiene un compuesto agonista dual del receptor tipo toll 7/8
PH12022551248A1 (en) 1,2,4-oxadiazole derivatives as liver x receptor agonists
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors